Article
Multidisciplinary Sciences
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Article
Oncology
Guilherme Nader-Marta, Veronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Summary: The sub-analysis of the ALTTO trial demonstrates that patients with small node-negative breast cancer treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Valentina Guarneri, Maria V. Dieci, Gaia Griguolo, Federica Miglietta, Fabio Girardi, Giancarlo Bisagni, Daniele G. Generali, Katia Cagossi, Samanta Sarti, Antonio Frassoldati, Lorenzo Gianni, Luigi Cavanna, Graziella Pinotti, Antonino Musolino, Federico Piacentini, Saverio Cinieri, Aleix Prat, PierFranco Conte
Summary: The Cher-LOB study demonstrated that the combination of lapatinib-trastuzumab plus chemotherapy is more effective in increasing pCR rate compared to other treatment options. The analysis confirmed the prognostic role of pCR and TILs, showing a potential for better outcomes with the lapatinib-trastuzumab combination. Luminal-A subtype was identified as a significant predictor for improved RFS.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
Summary: The study analyzed real-world data of patients with HER2-positive RPMGC treated with trastuzumab-based chemotherapy in a single center. The outcomes were comparable to the ToGA trial, and conversion surgery could be considered for suitable patients after a favorable response to chemotherapy.
Article
Oncology
Fangfang Duan, Muyi Zhong, Yuyu Ma, Chenge Song, Lehong Zhang, Ying Lin, Zhiyong Wu, Yuanqi Zhang, Jiajia Huang, Fei Xu, Yanxia Shi, Shusen Wang, Zhongyu Yuan, Wen Xia, Xiwen Bi
Summary: The switching mode showed superior efficacy compared to continuing mode in subsequent anti-HER2 therapy for patients with HER2-positive refractory metastatic breast cancer.
Article
Oncology
G. Griguolo, G. Serna, T. Pascual, R. Fasani, X. Guardia, N. Chic, L. Pare, S. Pernas, M. Munoz, M. Oliveira, M. Vidal, A. Llombart-Cussac, J. Cortes, P. Galvan, B. Bermejo, N. Martinez, R. Lopez, S. Morales, I Garau, L. Manso, J. Alarcon, E. Martinez, P. Villagrasa, A. Prat, P. Nuciforo
Summary: In HER2+ breast cancer, changes in the density of immune cells in the tumor microenvironment after anti-HER2 treatment, particularly those interacting spatially with tumor cells, are associated with treatment response. Furthermore, patients achieving pathologic complete response show a consistent decrease in stromal tumor-infiltrating lymphocytes (sTILs) post-surgery, while residual tumors often remain inflamed, suggesting a progressive loss of T cell function. Understanding the implications of the resulting immunosuppressive microenvironment is crucial for developing effective strategies for early-stage HER2+ breast cancer therapy.
NPJ PRECISION ONCOLOGY
(2021)
Article
Oncology
Neil A. O'Brien, Holly K. T. Huang, Martina S. J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Summary: In this preclinical study, a novel HER2-selective small-molecule inhibitor, tucatinib, demonstrated potent and selective activity in HER2-positive cancer cells. It showed tumor regression in xenograft models of HER2-positive breast cancer as a single agent, and when combined with trastuzumab, provided a complete and sustained blockade of HER2/PI3K/AKT signaling. The combination therapy of tucatinib and trastuzumab showed comparable efficacy to the current standard-of-care trastuzumab/pertuzumab/docetaxel combination, without the need for a dosing holiday to achieve the same efficacy. These findings suggest that tucatinib could be a potential therapeutic strategy for difficult-to-treat subtypes of HER2-positive breast cancer, and support further clinical investigations.
MOLECULAR CANCER THERAPEUTICS
(2022)
Article
Oncology
Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel
Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Oncology
Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jerusalem, Susan Dent, Linda Reaby, Herve Bonnefoi, Ian Krop, Tsang-Wu Liu, Tadeusz Pienkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young-Hyuck Im, Ling Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefania Monturus, Mihaela Sicoe, Sebastien Guillaume, Jose Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen
Summary: The PURPOSEAPHINITY study demonstrates that adding pertuzumab to adjuvant therapy with trastuzumab and chemotherapy significantly improves invasive disease-free survival for early HER2-positive breast cancer patients. Longer follow-up is needed for a comprehensive assessment of overall survival benefits.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Ricardo Fernandes, Terry L. Ng, Mashari Jemaan Alzahrani, Jacques Raphael, Phillip Blanchette, Morgan Black, Carol Stober, Gregory R. Pond, David Cella, Lisa Vandermeer, Mohammed Ibrahim, Mark Clemons, REaCT Investigators
Summary: This study compared the feasibility of two different drug regimens in treating HER2-positive early-stage breast cancer and found that both patients and doctors had a high acceptance rate and high treatment completion rate. However, the TC-H regimen had a higher rate of febrile neutropenia, and the P-H regimen had a smaller impact on patients' quality of life.
Article
Multidisciplinary Sciences
Young-Joon Kang, Se Jeong Oh, Soo Youn Bae, Eun-Kyu Kim, Young-Jin Lee, Eun Hwa Park, Joon Jeong, Heung Kyu Park, Young Jin Suh, Yong-Seok Kim
Summary: This study aimed to determine predictive factors for late survival in patients with HER2-positive breast cancer. It found that age, advanced tumor and lymph node stage, high histological grade, presence of lymphatic and vascular invasion, and hormone receptor-negative status were associated with poor overall survival. Node status had a more significant relationship with long-term prognosis than tumor stage in HER2-positive breast cancer patients.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Priya Rastogi, Gong Tang, Saima Hassan, Charles E. Geyer Jr, Catherine A. Azar, Gustav C. Magrinat, J. Marie Suga, Harry D. Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Francois Boileau, Adam M. Brufsky, Henry R. Shibata, Hanna Bandos, Soonmyung Paik, Greg Yothers, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark
Summary: This study aimed to compare the efficacy of trastuzumab alone or in combination with lapatinib in treating HER2-positive breast cancer patients. The results showed that although the combination therapy and the use of lapatinib had better outcomes, the differences were not statistically significant. However, achieving pathological complete response correlated with improved prognosis, especially in the ER-negative subset.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Alexios Matikas, Hemming Johansson, Per Gryback, Judith Bjohle, Balazs Acs, Ceren Boyaci, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Sara Margolin, Erika Isaksson-Friman, Ana Bosch, Henrik Lindman, Jamila Adra, Anne Andersson, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis
Summary: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present the survival outcomes from PREDIX HER2 and investigate metabolic response and tumor-infiltrating lymphocytes (TIL) as prognostic factors.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Yutian Zou, Shaoquan Zheng, Xinhua Xie, Feng Ye, Xiaoqian Hu, Zhi Tian, Shu-Mei Yan, Lu Yang, Yanan Kong, Yuhui Tang, Wenwen Tian, Jindong Xie, Xinpei Deng, Yan Zeng, Zhe-Sheng Chen, Hailin Tang, Xiaoming Xie
Summary: FGFR4 inhibition enhances sensitivity to anti-HER2 treatment in resistant breast cancer cells by triggering ferroptosis.
NATURE COMMUNICATIONS
(2022)
Article
Pathology
Clara Salas, Javier Martin-Lopez, Antonio Martinez-Pozo, Teresa Hernandez-Iglesias, David Carcedo, Lucia Ruiz de Alda, J. Francisco Garcia, Federico Rojo
Summary: This study aimed to describe the testing rate and frequency of molecular alterations observed in the Lung Cancer Biomarker Testing Registry. Results showed a high testing rate for EGFR and ALK, but a low rate for ROS1 and PD-L1. The study provides crucial information to improve molecular testing coverage in lung cancer and monitor the positivity rate.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Oncology
J. Albanell, M. T. Martinez, M. Ramos, M. O'Connor, L. de la Cruz-Merino, A. Santaballa, N. Martinez-Janez, F. Moreno, I Fernandez, J. Alarcon, J. A. Virizuela, J. de la Haba-Rodriguez, P. Sanchez-Rovira, L. Gonzalez-Cortijo, M. Margeli, A. Sanchez-Munoz, A. Anton, M. Casas, S. Bezares, F. Rojo
Summary: The study demonstrates that palbociclib/fulvestrant provides better progression-free survival rates and median progression-free survival compared to placebo/fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative endocrine-sensitive advanced breast cancer patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young-Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling-Ming Tseng, Mei-Ching Liu, Begona Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de la Haba-Rodriguez, Do-Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Summary: In HER2-positive/ER-positive breast cancer, the 41-gene classifier TRAR has been identified as an independent predictor of pCR, serving as a promising tool to select patients responsive to anti-HER2-based neoadjuvant therapy and to assist in treatment escalation and de-escalation strategies.
MOLECULAR ONCOLOGY
(2022)
Article
Rehabilitation
Antonio Cuesta-Vargas, Jena Buchan, Emilio Alba, Marcos Iglesias Campos, Cristina Roldan-Jimenez, Bella Pajares
Summary: A physical function test based on lie-to-sit transition was developed and its feasibility in patients with metastatic breast cancer (MBC) was studied. The 30-second lie-to-sit test showed to be a feasible functional and submaximal test in a sample of MBC.
DISABILITY AND REHABILITATION
(2023)
Article
Oncology
Miguel Martin, Christoph Zielinski, Manuel Ruiz-Borrego, Eva Carrasco, Eva M. Ciruelos, Montserrat Munoz, Begona Bermejo, Mireia Margeli, Tibor Csoszi, Antonio Anton, Nicholas Turner, Maria Casas, Serafin Morales, Emilio Alba, Lourdes Calvo, Juan De La Haba-Rodriguez, Manuel Ramos, Laura Murillo, Ana Santaballa, Jose L. Alonso-Romero, Pedro Sanchez-Rovira, Massimo Corsaro, Xin Huang, Christiane Thallinger, Zsuzsanna Kahan, Miguel Gil-Gil
Summary: In the PEARL phase III study, palbociclib plus endocrine therapy did not show a statistically superior overall survival compared to capecitabine in aromatase inhibitor-resistant, hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer patients. Subsequent systemic therapies and PFS2 were also analyzed and showed no significant differences between the study arms. The findings suggest that palbociclib plus endocrine therapy is not the preferred treatment option for these patients.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
M. Jose Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gomez-Espana, Juan R. De la Haba-Rodriguez, Antonio Rodriguez-Ariza, Enrique Aranda
Summary: This study aimed to evaluate the potential value of circulating plasma biomarkers in patients with metastatic colorectal cancer (mCRC) prior to first-line treatment. The findings indicated that high VEGF-A and low ACE plasma levels were associated with poor overall survival (OS) after treatment. Additionally, a simple scoring system combining these biomarkers efficiently stratified patients into high- or low-risk groups, aiding in the selection of patients for anti-angiogenic therapy.
Article
Oncology
C. E. Geyer, J. E. Garber, R. D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A. C. Armstrong, M. Arnedos, J. Balmana, J. Bergh, J. Bliss, S. Delaloge, S. M. Domchek, A. Eisen, F. Elsafy, L. E. Fein, A. Fielding, J. M. Ford, S. Friedman, K. A. Gelmon, L. Gianni, M. Gnant, S. J. Hollingsworth, S-A Im, A. Jager, S. R. Lakhani, W. Janni, B. Linderholm, T-W Liu, N. Loman, L. Korde, S. Loibl, P. C. Lucas, F. Marme, E. Martinez de Duenas, R. McConnell, K-A Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, P. Sharma, C. F. Singer, T. Spanic, E. Stickeler, M. Toi, T. A. Traina, G. Viale, G. Zoppoli, Y. H. Park, R. Yerushalmi, H. Yang, D. Pang, K. H. Jung, A. Mailliez, Z. Fan, I Tennevet, J. Zhang, T. Nagy, G. S. Sonke, Q. Sun, M. Parton, M. A. Colleoni, M. Schmidt, A. M. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A. N. J. Tutt, O. Th Johannsson
Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Joan Albanell, Jose Manuel Perez-Garcia, Miguel Gil-Gil, Giuseppe Curigliano, Manuel Ruiz-Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet, Begona Bermejo, Lourdes Calvo, Juan de la Haba, Enrique Espinosa, Alessandro Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menendez, Miguel Sampayo-Cordero, Crina Popa, Andrea Malfettone, Javier Cortes, Antonio Llombart-Cussac
Summary: This study assessed the efficacy and biomarkers of continuing palbociclib plus endocrine therapy in patients with advanced breast cancer who had progression on prior palbociclib-based regimen. The results suggest that maintaining palbociclib after progression may be a reasonable approach for selected patients, and a biomarker signature predicts a subset of patients who may not derive greater benefit from palbociclib rechallenge.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Grazia Arpino, Juan de la Haba Rodriguez, Jean -Marc Ferrero, Sabino De Placido, Dirk Klingbiel, Valentine Revelant, Christine Wohlfarth, Raf Poppe, Mothaffar F. Rimawi
Summary: The addition of pertuzumab to trastuzumab and an aromatase inhibitor significantly improved progression-free survival in patients with previously untreated HER2-positive and hormone receptor-positive breast cancer. The treatment effect of pertuzumab may be enhanced in patients who do not require chemotherapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Summary: Capivasertib-fulvestrant therapy significantly improves progression-free survival in patients with hormone receptor-positive advanced breast cancer, particularly those with AKT pathway alterations.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, Research & Experimental
Silvia Guil-Luna, Aurora Rivas-Crespo, Carmen Navarrete-Sirvent, Ana Mantrana, Alejandra Pera, Rafael Mena-Osuna, Marta Toledano-Fonseca, Maria Victoria Garcia-Ortiza, Carlos Villar, Maria Teresa Sanchez-Montero, Janna Krueger, Francisco Javier Medina-Fernandez, Juan De La Haba-Rodriguez, Auxiliadora Gomez-Espana, Enrique Aranda, Christopher E. Rudd, Antonio Rodriguez-Ariza
Summary: Our study provides compelling evidence for the clinical significance of GSK-3 expression and TB grade in risk stratification of colorectal cancer (CRC) patients. Moreover, our findings strongly support GSK-3 inhibition as an effective therapy specifically targeting high-grade TB in CRC.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Ariadna Tibau, M. Teresa Martinez, Manuel Ramos, Luis de la Cruz-Merino, Ana Santaballa, Miriam O'Connor, Noelia Martinez-Janez, Fernando Moreno, Isaura Fernandez, Juan Antonio Virizuela, Jesus Alarcon, Juan de la Haba-Rodriguez, Pedro Sanchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muino, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell
Summary: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2- advanced breast cancer (ABC). Health-related quality of life (QoL) was assessed using patient-reported outcomes (PROs). The combination of palbociclib/fulvestrant was found to be a beneficial therapeutic option for HR+/HER2- ABC, as it improved both PFS and QoL.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumi, Elena Aguirre, Miguel Angel Segui, Manuel Atienza, Silvia Diaz-Cerezo, Alberto Molero, Jose Manuel Cervera, Joaquin Gavila
Summary: This retrospective study in Spain found that abemaciclib is effective for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. It can be used as monotherapy or in combination with endocrine therapy.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Juan de la Haba-rodriguez, Ferran Ferragut Lloret, Maria Angeles Vaz Salgado, Martin Ore Arce, Ana Cardena Gutierrez, Jesus Garcia-Donas Jimenez, Carmen Beato Zambrano, Rosa Maria Rodriguez Alonso, Rafael Lopez Lopez, Nuria Rodriguez Salas
Summary: The improvement of molecular alterations in cancer and the development of technology have allowed us to more accurately determine molecular alterations in the diagnosis and treatment of cancer in clinical practice. The use of multidetermination platforms is becoming more widespread in Spanish hospitals. The objective of these clinical practice guides is to review their usefulness and establish guidelines for their incorporation into clinical practice.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)